|
On December 6, 7, and 8, 2017, Wilson Sonsini Goodrich & Rosati will be hosting its third Healthcare Innovations Venture Investment Forum. The Forum will be held at The University of Texas in Austin’s Dell Medical School.
Each of the participating investors will separately review company submissions and select the companies with which they would like to meet. Companies selected for a meeting with any investor during the Forum will have the opportunity to meet privately with the investor for about 40 minutes.
There is no charge for companies to participate.
Investors participating live include: 5AM Ventures, AbbVie Biotech Ventures, Apple Tree Partners, Atlas Venture, ARCH Venture Partners, Bain Capital, Bay City Capital, Deerfield, Fortress Biotech, Gurnet Point Capital, HIG Capital, Illumina Ventures, Integra LifeSciences Holdings, J&J Innovations, Lilly Ventures, Merck Global Health Innovation Fund, NEA, Novartis Institutes for Biomedical Research, Novo Ventures, Sailing Capital, Siemens Healthineers, Taiho Ventures, 3M Ventures, 8VC, Accelerator Corp., Apex Landmark, Charles River Ventures, Hatteras Venture Partners, Live Oak Venture Partners, Mercury Fund, MP Healthcare Venture Management, S3 Ventures, Sante Ventures, Thiel Capital, Translink Capital Partners, Cartmell VC, and KdT Ventures.
Additionally, Foresite Capital, Founder’s Fund, F-Prime Capital Partners, Frazier Healthcare, GE Ventures, OrbiMed, Pivotal bioVenture Partners, TPG, and Versant Ventures will be reviewing executive summaries and following up with company’s independently.
In order to be considered:
- Email your executive summary and non-confidential deck to Matt Bresnahan <mbresnahan@wsgr.com> with the company name in the subject line.
- Deadline for submitting executive summaries for consideration is September 15.
Additional VCs may be participating in this event or may request to separately review the executive summaries. If you prefer that we not provide the executive summaries to any investors other than those indicated above, please indicate this preference when emailing your executive summary and non-confidential deck.
Please feel free to contact me with any questions you may have.
|
